Liposomal irinotecan plus fluorouracil/leucovorin in older patients with advanced pancreatic cancer: a single-center retrospective study

被引:1
作者
Nagashima, Shuhei [1 ,2 ]
Kobayashi, Satoshi [1 ]
Tsunoda, Shotaro [1 ]
Yamachika, Yui [1 ]
Tozuka, Yuichiro [1 ]
Fukushima, Taito [1 ]
Morimoto, Manabu [1 ]
Ueno, Makoto [1 ]
Furuse, Junji [1 ]
Maeda, Shin [2 ]
机构
[1] Kanagawa Canc Ctr, Dept Gastroenterol, 2-3-2 Nakao,Asahi Ku, Yokohama 2418515, Japan
[2] Yokohama City Univ, Dept Gastroenterol, Grad Sch Med, 3-9 Fukuura,Kanazawa Ku, Yokohama 2360004, Japan
关键词
Liposomal irinotecan; Fluorouracil/leucovorin; Aging; Pancreatic ductal adenocarcinoma; Second-line treatment; NAPOLI-1; trial; POST-HOC ANALYSIS; NAB-PACLITAXEL; GEMCITABINE; MULTICENTER; DETERMINANT; SARCOPENIA;
D O I
10.1007/s10147-023-02432-9
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background The global phase 3 NAPOLI -1 trial of patients with pancreatic ductal adenocarcinoma (PDAC) demonstrated an overall survival (OS) benefit from using liposomal irinotecan and 5-fluorouracil/leucovorin (nal-IRI + 5-FU/LV) after treatment with gemcitabine (GEM) compared to 5-FU/LV alone. However, the efficacy and safety of this regimen in older patients are not well studied.Methods We conducted a single-center retrospective study to compare the therapeutic efficacy of nal-IRI + 5-FU/LV between older and younger patients with cutoff ages of 70 and 75 years, respectively. We included patients with a prior history of one or more GEM-based regimens for locally advanced or metastatic PDAC and were treated with nal-IRI + 5-FU/LV.Results Of the 115 patients, 54 (47.0%) and 24 (20.9%) were aged >= 70 and >= 75 years, respectively. The median OS and progression-free survival (PFS) of the entire cohort were 8.5 and 3.6 months, respectively. No significant differences were observed in OS and PFS hazard ratios using age cutoffs of 70 (P = 0.90 and 0.99, respectively) and 75 (P = 0.90 and 0.76, respectively) years. Additionally, no significant differences were found in the incidence of treatment-related adverse events (trAEs) between patients aged >= 70 and < 70 years or those aged >= 75 and < 75 years. Other than hematological toxicity, no trAEs higher than Grade 4 were observed in either age group.Conclusion The efficacy and safety of nal-IRI + 5-FU/LV for patients with PDAC are not significantly different for those aged >= 70 years compared to younger patients.
引用
收藏
页码:188 / 194
页数:7
相关论文
共 22 条
[1]  
[Anonymous], COMMON TERMINOLOGY C
[2]   Sarcopenia Prognostic Value for Unresectable Pancreatic Ductal Adenocarcinoma Patients Treated With Gemcitabine Plus Nab-Paclitaxel [J].
Asama, Hiroyuki ;
Ueno, Makoto ;
Kobayashi, Satoshi ;
Fukushima, Taito ;
Kawano, Kuniyuki ;
Sano, Yusuke ;
Tanaka, Satoshi ;
Nagashima, Shuhei ;
Morimoto, Manabu ;
Ohira, Hiromasa ;
Maeda, Shin .
PANCREAS, 2022, 51 (02) :148-152
[3]  
Cancer Statistics, About us
[4]   European cancer mortality predictions for the year 2020 with a focus on prostate cancer [J].
Carioli, G. ;
Bertuccio, P. ;
Boffetta, P. ;
Levi, F. ;
La Vecchia, C. ;
Negri, E. ;
Malvezzi, M. .
ANNALS OF ONCOLOGY, 2020, 31 (05) :650-658
[5]   Early dose reduction/delay and the efficacy of liposomal irinotecan with fluorouracil and leucovorin in metastatic pancreatic ductal adenocarcinoma (mPDAC): A post hoc analysis of NAPOLI-1 [J].
Chen, Li-Tzong ;
Macarulla, Teresa ;
Blanc, Jean-Frederic ;
Mirakhur, Beloo ;
de Jong, Floris A. ;
Belanger, Bruce ;
Bekaii-Saab, Tanios ;
Siveke, Jens T. .
PANCREATOLOGY, 2021, 21 (01) :192-199
[6]   FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer [J].
Conroy, Thierry ;
Desseigne, Francoise ;
Ychou, Marc ;
Bouche, Olivier ;
Guimbaud, Rosine ;
Becouarn, Yves ;
Adenis, Antoine ;
Raoul, Jean-Luc ;
Gourgou-Bourgade, Sophie ;
de la Fouchardiere, Christelle ;
Bennouna, Jaafar ;
Bachet, Jean-Baptiste ;
Khemissa-Akouz, Faiza ;
Pere-Verge, Denis ;
Delbaldo, Catherine ;
Assenat, Eric ;
Chauffert, Bruno ;
Michel, Pierre ;
Montoto-Grillot, Christine ;
Ducreux, Michel .
NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (19) :1817-1825
[7]   Development of a highly active nanoliposomal irinotecan using a novel intraliposomal stabilization strategy [J].
Drummond, DC ;
Noble, CO ;
Guo, ZX ;
Hong, K ;
Park, JW ;
Kirpotin, DB .
CANCER RESEARCH, 2006, 66 (06) :3271-3277
[8]   Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upaEuro [J].
Ducreux, M. ;
Cuhna, A. Sa. ;
Caramella, C. ;
Hollebecque, A. ;
Burtin, P. ;
Goere, D. ;
Seufferlein, T. ;
Haustermans, K. ;
Van Laethem, J. L. ;
Conroy, T. ;
Arnold, D. .
ANNALS OF ONCOLOGY, 2015, 26 :V56-V68
[9]   New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1) [J].
Eisenhauer, E. A. ;
Therasse, P. ;
Bogaerts, J. ;
Schwartz, L. H. ;
Sargent, D. ;
Ford, R. ;
Dancey, J. ;
Arbuck, S. ;
Gwyther, S. ;
Mooney, M. ;
Rubinstein, L. ;
Shankar, L. ;
Dodd, L. ;
Kaplan, R. ;
Lacombe, D. ;
Verweij, J. .
EUROPEAN JOURNAL OF CANCER, 2009, 45 (02) :228-247
[10]   Predicting Chemotherapy Toxicity in Older Patients with Cancer: A Multicenter Prospective Study [J].
Feliu, Jaime ;
Jimenez-Munarriz, Beatriz ;
Basterretxea, Laura ;
Paredero, Irene ;
Llabres, Elisenda ;
Antonio-Rebollo, Maite ;
Losada, Beatriz ;
Espinosa, Enrique ;
Girones, Regina ;
Belen Custodio, Ana ;
del Mar Munoz, Maria ;
Diaz-Almiron, Mariana ;
Gomez-Mediavilla, Jeniffer ;
Pinto, Alvaro ;
Torregrosa, Maria-Dolores ;
Soler, Gema ;
Cruz, Patricia ;
Higuera, Oliver ;
Jose Molina-Garrido, Maria .
ONCOLOGIST, 2020, 25 (10) :E1516-E1524